ArticleIJID regions2025
The prevalence of rotavirus infection among Congolese children younger than 5 years hospitalized for gastroenteritis 10 years after introduction of rotavirus vaccination.
Article in IJID regions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Beyond Rotavirus: Persistence of Norovirus, Adenovirus, and Astrovirus in Paediatric Gastroenteritis in the Republic of Congo After Vaccine Introduction.Journal of medical virology · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Rotavirus A (RVA) remains the primary cause of acute severe gastroenteritis associated with high rates of childhood hospitalization and mortality worldwide. The prevalence of RVA infection varies within low-income countries. In addition, its genetic diversity may vary among regions and may affect its prevalence. To control the emergence of new strains of RVA circulating in the Republic of Congo, it is essential to know the diversity of both G and P genotypes, which could render the vaccine less effective. Therefore, this study aimed to determine the prevalence and genotype diversity of RVA strains in children who were hospitalized, whether vaccinated or not. Moreover, the potential risk factors of disease severity are identified. Methods: The study was conducted from April 2022 to March 2023. Stool samples were collected from children younger than 5 years, hospitalized in a pediatric ward for acute gastroenteritis, and a commercial enzyme-linked immunosorbent assay (ELISA) was used to detect RVA cases. In parallel, a multiplex reverse transcription-polymerization chain reaction (RT-PCR) was performed for RVA detection and genotyping. All samples with ambiguous multiplex RT-PCR results were subjected to sequencing. Results: A total of 227 children hospitalized were enrolled and tested for RVA infection. Using ELISA and PCR, 59 (26%) and 131 (57.7%) individuals were found to be infected with RVA, respectively. All individuals with a positive ELISA test result were confirmed as RVA-positive by PCR. Of the 98 children with documented histories of RVA vaccination, 60% presented with RVA infection. The occurrence of vomiting on more than three occasions within a 24-hour period and the time between vaccination and sample collection were found to be associated with RVA infection. RVA genotyping revealed six P types (P[4]; P[6]; P[8]; P[9]; P[10]; and P[11]). The predominant genotypes were (P[4] 15.3%; P[6] 13.7%; P[8] 22.1%; P[9] 14.5%). Among the eight G types, the most prevalent were G3 (13.7%), G4 (12.2%), and G1 (6.9%). No specific genotype distribution was discernible as a function of vaccination history. Conclusions: Compared with the findings of our study before the implementation of rotavirus vaccination, in this report, we observed a roughly 20% decreased prevalence of RVA infection in children hospitalized. The results suggest that in Brazzaville at least, 10 years of rotavirus vaccination in the Republic of Congo have had a substantial effect, despite the reported reduced efficacy of the vaccines in low- and middle-income countries. The findings thus support enhanced efforts to increase coverage through national vaccination programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.